Literature DB >> 20010160

Hyperammonemic encephalopathy: a rare presentation of fibrolamellar hepatocellular carcinoma.

Saurabh Sethi1, Nishant Tageja, Jatinder Singh, Haitham Arabi, Maneesh Dave, Apurva Badheka, Sanjay Revankar.   

Abstract

Fibrolamellar carcinoma (FLC) is a rare malignant hepatocellular tumor of unknown etiology, arising almost exclusively from noninfected, noncirrhotic liver of young adults. FLC has traditionally been considered to have better survival than hepatocellular carcinoma; however, this notion might be highly erroneous. Patients with metastatic disease at presentation have a dismal prognosis with 5-year survival of only 15%. We describe a case of highly aggressive metastatic FLC that presented as hyperammonemic encephalopathy, which has never been previously reported in the literature.

Entities:  

Mesh:

Year:  2009        PMID: 20010160     DOI: 10.1097/MAJ.0b013e3181bccfb4

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  13 in total

1.  Hyperammonemic encephalopathy in a patient with fibrolamellar hepatocellular carcinoma: case report and literature review.

Authors:  Janice Cho; Joy C Y Chen; Jonas Paludo; Erin E Conboy; Brendan C Lanpher; Steven R Alberts; Thorvardur R Halfdanarson
Journal:  J Gastrointest Oncol       Date:  2019-06

2.  Hepatocellular Carcinoma of Fibrolamellar Type in an Adolescent: Case Report and Literature Review.

Authors:  Javier Santiago-Reynoso; Karina Senyase Zamaripa-Martínez; Juan Manuel Dorantes-Loya; Guillermo J Gaytán-Fernández; Evelia Apolinar-Jiménez; Francisco Paz-Gómez; Felipe Farias-Serratos; María Maldonado-Vega
Journal:  Gastrointest Tumors       Date:  2019-05-27

3.  Molecular characteristics of fibrolamellar hepatocellular carcinoma.

Authors:  Attila Patonai; Boglárka Erdélyi-Belle; Anna Korompay; Aron Somorácz; Péter Törzsök; Ilona Kovalszky; Tamás Barbai; Erzsébet Rásó; Gábor Lotz; Zsuzsa Schaff; András Kiss
Journal:  Pathol Oncol Res       Date:  2012-08-08       Impact factor: 3.201

4.  Fibrolamellar hepatocellular carcinoma mimicking ornithine transcarbamylase deficiency.

Authors:  Raashda A Sulaiman; Tarekegn Geberhiwot
Journal:  JIMD Rep       Date:  2014-07-05

5.  Hyperammonemic Encephalopathy Associated With Fibrolamellar Hepatocellular Carcinoma: Case Report, Literature Review, and Proposed Treatment Algorithm.

Authors:  Claudia I Chapuy; Inderneel Sahai; Rohit Sharma; Andrew X Zhu; Olga N Kozyreva
Journal:  Oncologist       Date:  2016-03-14

6.  Hyperammonemic encephalopathy in an adenocarcinoma patient managed with carglumic acid.

Authors:  J Lazier; S M Lupichuk; I Sosova; A A Khan
Journal:  Curr Oncol       Date:  2014-10       Impact factor: 3.677

7.  The genomic landscape of fibrolamellar hepatocellular carcinoma: whole genome sequencing of ten patients.

Authors:  David G Darcy; Rachel Chiaroni-Clarke; Jennifer M Murphy; Joshua N Honeyman; Umesh Bhanot; Michael P LaQuaglia; Sanford M Simon
Journal:  Oncotarget       Date:  2015-01-20

8.  Successful Liver Transplantation for Hyperammonemic Fibrolamellar Hepatocellular Carcinoma.

Authors:  Angel E Alsina; Edson Franco; Ahmad Nakshabandi; Christopher Albers; Nyingi Kemmer; Andrew C Berry; Jon Finan
Journal:  ACG Case Rep J       Date:  2016-08-17

9.  A Proposed Physiopathological Pathway to Hyperammonemic Encephalopathy in a Non-Cirrhotic Patient with Fibrolamellar Hepatocellular Carcinoma without Ornithine Transcarbamylase (OTC) Mutation.

Authors:  Rodrigo C Surjan; Elizabeth S Dos Santos; Tiago Basseres; Fabio F Makdissi; Marcel A Machado
Journal:  Am J Case Rep       Date:  2017-03-08

Review 10.  Fibrolamellar hepatocellular carcinoma: current clinical perspectives.

Authors:  Kelly J Lafaro; Timothy M Pawlik
Journal:  J Hepatocell Carcinoma       Date:  2015-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.